Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Examining the Use of Pill Swallowing in Dysphagia Assessment: A Survey of Common Practices.

Dysphagia·2025
Same author

Making Sense: Feasibility of an education program to Empower adults with type 1 diabetes to interpret CGM data.

Diabetes research and clinical practice·2025
Same author

"Empowering Us": A community-led survey of real-world perspectives of adults with type 1 diabetes using insulin pumps and continuous glucose monitoring to manage their glucose levels.

Diabetes research and clinical practice·2023
Same author

Disparities in Acute Coronary Syndrome Outcomes in Individuals With Intellectual Disabilities: A Propensity-Matched Analysis of National Inpatient Sample.

Cardiovascular revascularization medicine : including molecular interventions·2023
Same author

Vessel and Muscle Sparing Techniques in Bulbous Urethroplasty: A Review.

Urology practice·2023
Same author

Early Postoperative Complications and Factors Associated with Early vs Late Discharge of Patients Undergoing Colporrhaphy for Pelvic Organ Prolapse: A National Report.

Urology practice·2023

Related Experiment Video

Updated: Mar 28, 2026

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.9K

Post-Chemotherapy Robotic Retroperitoneal Lymph Node Dissection: Institutional Experience.

Mohamed H Kamel1,2, Nathan Littlejohn1, Michelle Cox3

  • 11 Department of Urology, University of Arkansas for Medical Sciences , Little Rock, Arkansas.

Journal of Endourology
|December 17, 2015
PubMed
Summary
This summary is machine-generated.

Robotic retroperitoneal lymph node dissection is feasible for post-chemotherapy residual masses, showing low blood loss and short hospital stays. Further research is needed to confirm long-term outcomes and compare with open surgery.

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.8K
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

1.4K

Related Experiment Videos

Last Updated: Mar 28, 2026

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

6.9K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.8K
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

1.4K

Area of Science:

  • Urology
  • Surgical Oncology
  • Minimally Invasive Surgery

Background:

  • Robotic retroperitoneal lymph node dissection (RRPLND) literature is scarce for post-chemotherapy (PC) residual masses.
  • This study evaluates the outcomes of RRPLND in patients with PC-residual masses.

Purpose of the Study:

  • To assess the feasibility and outcomes of robotic retroperitoneal lymph node dissection (RRPLND) in patients with post-chemotherapy residual masses.
  • To evaluate the morbidity, operative time, blood loss, and oncological outcomes of this procedure.

Main Methods:

  • Retrospective analysis of 12 patients undergoing PC-RRPLND between 2011 and 2015.
  • Data collected included patient demographics, tumor characteristics, International Germ Cell Cancer Collaborative Group (IGCCCG) classification, operative details, complications, and follow-up.
  • Pathology of excised masses was analyzed for teratoma, necrosis, or viable germ cells.

Main Results:

  • The procedure was completed effectively in 91.7% of patients.
  • Mean operative time was 312 minutes, mean estimated blood loss was 475 mL, and mean hospital stay was 3.2 days.
  • Pathology revealed teratoma in 45.5%, benign/necrosis in 45.5%, and viable germ cells in 9%. No relapses occurred at a median follow-up of 31 months.

Conclusions:

  • Robotic PC-retroperitoneal lymph node dissection (RPLND) is technically feasible with acceptable morbidity.
  • The procedure is associated with low blood loss and short hospital stays.
  • Further research is required to evaluate long-term outcomes and compare with standard open RPLND.